Bristol Myers Squibb Buys RayzeBio, Second Billion-Dollar Offer in Days. - Lavenhill Securities

CENTRAL, Hong Kong - Jan. 11, 2024 - PRLog -- It was Bristol Myers Squibb's second multibillion-dollar purchase in less than a week.

In a news statement, Bristol Myers Squibb said that it will pay RayzeBio shareholders $62.50 for each share they owned. This is a 104% premium over RayzeBio's Friday closing price.

RayzeBio is working on methods to attack cancer cells using radioactive particles. RayzeBio's current pipeline, according to Bristol Myers Squibb, includes initiatives to treat solid malignancies such as gastroenteropancreatic neuroendocrine tumors, small cell lung cancer, and hepatocellular carcinoma.

According to Bristol Myers Squibb CEO Christopher Boerner, radiopharmaceutical treatments are already revolutionizing cancer care, and RayzeBio "enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline."

The business said that it intends to fund the transaction via debt issuance. The deal is likely to close in the first half of next year.

Bristol Myers Squibb announced a $14 billion acquisition of Karuna Therapeutics Inc. on Friday to expand its neuroscience portfolio.

Lavenhill Securities Limited's firm is founded on integrity. We adhere to the highest ethical standards, ensuring that our clients' interests are always emphasized. Transparency and trust are critical in our client engagements. We emphasize client's specific financial objectives and risk profiles and adapt investing strategies appropriately. Please visit us at https://lavenhillsecuritiesl.com.